Patents Assigned to Sumitomo Dainippon Pharma Co., Ltd.
-
Publication number: 20210387967Abstract: Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, X4 represents CR4 or N, Y represents optionally substituted C1-6 alkyl, an optionally substituted C3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R1, R2, R3, and R4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or the like.Type: ApplicationFiled: August 24, 2021Publication date: December 16, 2021Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Kazuto MORI, Hiroyuki KITANO, Tomoyuki FURUTA, Hajime SEKI, Yohei KOBAYASHI
-
Publication number: 20210380598Abstract: The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X1 represents CR or N, X2 represents CR2 or N, X3 represents CR3 or N, Y represents an optionally substituted C6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C6-10 aryl, RA represents a hydrogen atom, halogen, cyano, optionally substituted C1-6 alkyl sulfonyl, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy, and R1, R2, and R3 independently represent a hydrogen atom, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 3, 2021Publication date: December 9, 2021Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventor: Tomoyuki FURUTA
-
Publication number: 20210346303Abstract: Provided is a method for producing particles coated by a coatable first polymer and a lubricant. A method for producing particles coated by a first polymer and a lubricant, wherein the production method is characterized by: including a step for adding a first polymer and a lubricant to core particles that include a component of interest and a second polymer, and coating while rolling the mixture and spraying a solvent capable of dissolving the first polymer; and the particles coated by the first polymer and lubricant being component of interest-containing hollow particles.Type: ApplicationFiled: October 17, 2019Publication date: November 11, 2021Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Mitsuaki KOBIKI, Takumi ASADA
-
Publication number: 20210338587Abstract: The present invention relates to a lyophilized preparation comprising two or more cancer antigen peptides derived from WT1 protein with an activity of inducing cytotoxic T lymphocytes for cancer peptide vaccine therapy.Type: ApplicationFiled: September 27, 2019Publication date: November 4, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Akihiro MORITA, Takuma TSUZUKU, Yuko YOSHINAGA
-
Publication number: 20210338852Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.Type: ApplicationFiled: July 2, 2021Publication date: November 4, 2021Applicants: NIHON MEDI-PHYSICS CO., LTD., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Norihito Nakata, Nobuya Kobashi, Yoshinari Shoyama, Mitsuhiro Matono, Yasushi Ochiai, Takayuki Murakami
-
Publication number: 20210338170Abstract: Provided is a method for assessing a correlation degree and an influence degree between a health degree in a health domain of concern and each preventive interventional action, based on biological information acquired in a time-series manner. The method comprises: acquiring biological information of an individual in a time-series manner; performing, based on the acquired biological information, an assessment of a health degree of the individual in a time-series manner; acquiring an intervention amount of each of one or more preventive interventional actions in a time-series manner; deriving a correlation degree and an influence degree between the time-series intervention amount of each of the one or more preventive interventional actions and the time-series health degree of the individual; and determining, as a relevant preventive interventional action, a preventive interventional action whose correlation degree is a given value or more, among the one or more preventive interventional actions.Type: ApplicationFiled: October 11, 2019Publication date: November 4, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yasushi OCHIAI, Minoru YOSHIMIZU, Mitsuhiro MATONO
-
Publication number: 20210338668Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: August 26, 2019Publication date: November 4, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Hitoshi BAN, Naoaki SHIMADA, Wataru HIROSE, Akihiko ARAKAWA, Kazuto YAMAZAKI, Kenjiro HIRA
-
Publication number: 20210332025Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.Type: ApplicationFiled: April 23, 2021Publication date: October 28, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidefumi YOSHINAGA, Hiro UEMACHI, Tomomi OHNO, Jeremy BESNARD
-
Publication number: 20210322385Abstract: The present invention pertains to a drug for the treatment and/or prevention of pain, more specifically to a medicinal preparation for external use to treat and/or prevent peripheral neuropathic pain, the medicinal preparation containing as an active ingredient N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide.Type: ApplicationFiled: July 18, 2019Publication date: October 21, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Masayasu TANAKA, Yoshihiro OYAMADA, Yoshinori TAKADA
-
Patent number: 11147811Abstract: The present invention relates to a comprising (A) an active ingredient which is hardly soluble in water, but soluble in a C1-4 lower alcohol that may contain 30 vol % or less water, (B) polyvinyl alcohol having a saponification rate of 55-99%, and (C) a non-ionic surfactant, wherein the (A) active ingredient has a mean particle size of 10-300 nm, and a process thereof.Type: GrantFiled: March 9, 2017Date of Patent: October 19, 2021Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventor: Shunsuke Saito
-
Publication number: 20210299099Abstract: The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.Type: ApplicationFiled: January 12, 2018Publication date: September 30, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Taro KATO, Satoko SHIMIZU
-
Publication number: 20210230558Abstract: An object of the present invention is to provide a dispersion of pluripotent stem cells and a pluripotent stem cell product having a suitable quality as a pharmaceutical or a raw material for producing a pharmaceutical which can be stored and distributed, and a method for producing the same. The method for producing a pluripotent stem cell product of the present invention comprises (1) culturing pluripotent stem cells in an undifferentiation maintenance medium; (2) suspending the pluripotent stem cells cultured in step (1) in a first medium for suspending cells containing a ROCK inhibitor; (3) replacing the medium for suspending cells of a suspension obtained in step (2) with a medium for cryopreservation to obtain a cell dispersion solution consisting of the medium for cryopreservation and the pluripotent stem cells dispersed in the medium for cryopreservation; and (4) filling the cell dispersion solution obtained in step (3) into an airtight container so as to be in an airtight state.Type: ApplicationFiled: July 10, 2019Publication date: July 29, 2021Applicants: Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Chemical Company, LimitedInventors: Atsushi Kuwahara, Naoki Takamura, Ayaka Fujiki, Tetsuya Hayama, Hidetaka Ohara
-
Patent number: 11066372Abstract: The present invention relates to a medicament for treating or preventing a disease involving Na channel, for example, neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, or multiple sclerosis, comprising a compound of formula (I) wherein R1a, R1b, R1c, and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, etc., provided that at least one of R1a, R1b, R1c and R1d is the above C6-10 aryl, C6-10 aryloxy, etc., R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, etc., R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, etc., m is 0, 1, or 2, L is CR7R8, R7 and R8 are hydrogen, hydroxy group, C1-4 alkyl, C1-4 alkoxy, etc., or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 14, 2018Date of Patent: July 20, 2021Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Toshio Kanai, Kohei Iwamoto
-
Patent number: 11066425Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: GrantFiled: December 29, 2020Date of Patent: July 20, 2021Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTEInventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
-
Publication number: 20210198242Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: ApplicationFiled: October 26, 2020Publication date: July 1, 2021Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
-
Publication number: 20210198283Abstract: The present invention relates to the compound of formula (Ia) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.Type: ApplicationFiled: August 7, 2019Publication date: July 1, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji KAMIOKA, Naoaki SHIMADA, Hitoshi BAN, Kazuto YAMAZAKI, Akihiko ARAKAWA, Wataru HIROSE
-
Publication number: 20210165002Abstract: The present invention provides a polypeptide consisting of any of the following amino acid sequences and useful for determining Alzheimer's disease: (1) the amino acid sequence shown in SEQ ID NO: 1; and (2) an amino acid sequence resulting from substitution, deletion, addition or insertion of one to several amino acids in the amino acid sequence shown in SEQ ID NO: 1.Type: ApplicationFiled: August 6, 2019Publication date: June 3, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Atsushi ONO, Yasuhiro TERANISHI, Masanori KUSUMOTO, Masakazu HASHIMOTO, Shoji KASHIWABARA, Maki HASHIMOTO
-
Publication number: 20210154370Abstract: The present invention aims to provide a method for suppressing differentiation of ganglion cell, amacrine cell, horizontal cell and/or bipolar cell in a neural retina tissue containing photoreceptor precursor and/or photoreceptor, and the like. A method for suppressing differentiation of a ganglion cell, an amacrine cell, a horizontal cell and/or a bipolar cell in a neural retinal tissue containing a photoreceptor precursor and/or a photoreceptor, including a step of culturing a retinal tissue comprising a neural retinal progenitor cell and in any stage between a differentiation stage immediately after emergence of a ganglion cell and a differentiation stage where emergence rate of a cone photoreceptor precursor reaches maximum in a medium containing a thyroid gland hormone signal transduction pathway agonist.Type: ApplicationFiled: September 14, 2018Publication date: May 27, 2021Applicants: RIKEN, SUMITOMO DAINIPPON PHARMA CO., LTD., SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Daiki NUKAYA, Mototsugu EIRAKU, Yuiko KINOSE, Akishi ONISHI, Masayo TAKAHASHI, Yoshiki SASAI (deceased)
-
Patent number: 11014905Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.Type: GrantFiled: March 12, 2018Date of Patent: May 25, 2021Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hidefumi Yoshinaga, Hiro Uemachi, Tomomi Ohno, Jeremy Besnard
-
Publication number: 20210147448Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: ApplicationFiled: April 26, 2019Publication date: May 20, 2021Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTEInventors: Toshio KANAI, Sachiko KOIKE, Takayuki FUKAYA, Shunichiro UESUGI, Shingo MIZUSHIMA, Hitoshi SUDA, Yuki MIZUKAMI, Yohei IKUMA, Toshiaki SUNAZUKA, Yoshihiko NOGUCHI